Both the Peregrine protein/nucleic acid analysis system and the Merlin DNA sequencer offer unrivalled sensitivity, ultra high-speed throughput and very low running costs, says the company
Deltadot, a developer of enabling technologies and products for bioscience research, has announced that Lathrop Engineering has been awarded the manufacturing contract for its first two commercial products, a protein/nucleic acid analysis system and a DNA sequencer.
These products are based on Deltadot's proprietary label free intrinsic imaging (LFII) technology.
Lathrop, an industrial design and engineering company based in California, is ISO 9001 certified and has over 20 years experience in the field of bioscience manufacturing with an exceptional track record in the development of biomedical instruments.
Advance sales of both units have already been made and the first shipments of these highly anticipated instruments are expected in December 2005.
Tony Baxter, CEO of Deltadot, said: "We are very impressed with Lathrop's manufacturing capabilities and are confident in their ability to deliver high-quality systems with fast delivery times.
"Having previously developed a range of biomedical products, including electrophoresis systems, Lathrop understands the stringent tolerances of this business and the requirements of manufacturing precision instrumentation.
"Its technical abilities, industry experience, and short development cycles are all advantages that we can pass on directly to our customers".
Deltadot's novel biomolecule detection technique, LFII, is derived from recent innovations in high-energy physics research and their application in modern biochemical analysis.
Unlike conventional techniques, the technology does not require target molecules to be labelled and therefore enables superior data quantification, while reducing throughput times, operating costs and health and safety issues.
"Both the management and engineering teams at Lathrop are tremendously excited to be working with Deltadot on the Peregrine and Merlin projects," said Bruce Richardson, VP of engineering for Lathrop.
"Founded in their background and field knowledge, both in the bioscience and particle physics, Deltadot has created a core set of technologies that offer immediately recognisable benefits.
"The ability to detect and quantify unlabelled proteins is a significant accomplishment and immensely important to the research and pharmaceutical development communities.
"This will also provide Deltadot with a substantial competitive advantage in the biomedical market and we look forward to sharing in their future success."
